metabolic clearance of ∼50% therapeutic drugs. CYP3A4 inhibitors have been used for improving the in vivo efficacy of hCYP3A4-substrate drugs. However, most of existing hCYP3A4 inhibitors may trigger serious adverse effects or undesirable effects on endogenous metabolism. This study aimed to discover potent and orally active hCYP3A4 inhibitors from chalcone derivatives and to test their anti-hCYP3A4
人细胞色素 P450 3A4 (hCYP3A4) 是最重要的药物代谢酶之一,催化约50% 治疗药物的代谢清除。CYP3A4
抑制剂已被用于提高hCYP3A4底物药物的体内功效。然而,大多数现有的hCYP3A4
抑制剂可能会引发严重的副作用或对内源代谢产生不良影响。本研究旨在从
查耳酮衍
生物中发现有效的口服活性 hCYP3A4
抑制剂,并在体外和体内测试其抗 hCYP3A4 作用。经过三轮筛选和结构优化,发现
异喹啉查尔酮类化合物具有优异的抗hCYP3A4作用。
SAR 研究表明,在 A 环上引入
异喹啉环可显着增强抗 CYP3A4 作用,产生A10 (IC 50 = 102.10 nM) 作为一种有前途的先导化合物。第二轮
SAR研究表明,在B环羰基对位引入取代基可显着提高抗CYP3A4效果。结果,C6被确定为人肝微粒体 (HLM) 中最有效的 hCYP3A4
抑制剂 (IC 50 = 43.93